Although CD19 is an attractive target in many malignancies, its efficacy has been mostly proven in acute lymphoblastic leukaemia (ALL) (Fda and Cber 2017; Kymriah 2018). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.